Textor, S.

Renal artery stenosis (RAS) may lead to hypertension and renal injury. Reversibility of renal tubular dysfunction in RAS upon revascularization is unclear. We tested the hypothesis that percutaneous transluminal renal angioplasty (PTRA) would restore tubular function assessed as medullary oxygenation response to furosemide, a diuretic that inhibits medullary tubular transport. This was studied in 16 pigs after 6 wks of RAS, using blood oxygen level dependent magnetic resonance imaging (BOLD MRI) before and after furosemide. Renal blood flow (RBF) and glomerular filtration rate (GFR) were determined with multidetector computed tomography. Pigs were then randomized for PTRA or sham (n=8 each) and studied again 4 wks later; 8 normal pigs served as controls. Results Stenotic kidney RBF, GFR, and BOLD MRI responses were reduced in RAS shams (Figure). PTRA decreased the degree of stenosis (11±7 vs. 71±5% in untreated RAS) and blood pressure (108±3 vs. 130±9 mmHg, p<0.05). Renal and tubular function were improved in RAS+PTRA, although not to normal (Figure). Non‐stenotic kidneys showed no change in tubular function. Therefore, tubular solute transport‐related oxygen consumption can be partially restored and detected by BOLD MRI 4 wks after PTRA in post stenotic swine kidneys. This noninvasive method may be useful to assess the functional status of kidneys in RAS patients. Supported by NIH, HL085307.

Purpose: To compare the clinical outcomes in patients with chronic renal insufficiency (CRI) and renal artery stenosis (RAS) following renal artery (RA) stent placement with and without embolic protection device (EPD) usage. Materials and Methods: Eighteen patients who had RA stent placement with EPD were matched to control patients (RA stent only). Blood pressure, number of hypertensive medications, and estimated glomerular filtration rate (eGFR) at 3 months before the procedure and after 12 months were determined. An increase of ≥ 20% in eGFR at 12 months from baseline was defined as “improvement,” decrease of ≥20% as “deterioration,” and an eGFR change between those values as “stabilization” at 12 months. Results: At 12 months, stage 4 patients treated with EPD had significantly higher eGFR than controls ( P = .01). There was no statistical difference in blood pressure outcomes between the 2 groups. Conclusions: Patients with stage 4 CRI did significantly better with EPD than those treated without it.